Phase 3 outcomes from NEJM SURMOUNT-1, SURPASS-2, STEP-1, and Lancet Orforglipron oral GLP-1 trials—plus hepatic dawn phenomenon physiology, 15-minute post-meal GLUT4 walks, and first-30-day Type 2 Diabetes remission protocols. Explore 704 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Diacerein as an add-on to metformin in patients with T2DM improved their blood sugar control.
ER niacin reduces apoB-48 concentration by lowering fasting and postprandial apoB-48 secretion rate.
However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP.
In this study, Japanese adults with EHT had significant increases in adiponectin after 3 months of treatment with 50 to 100 mg/d of losartan, but not with 5 to 10 mg/d of amlodipine.
This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.
The US Food and Drug Administration (FDA) authorized the first wearable device that continuously monitors ketone levels in people with type 1 diabetes.
Many men are failing to thrive. Shorter life expectancies for men than for woman first emerged in the 19th century and the gap has continued to widen (albeit with geographical variations). Men have a higher burden of illness: global disability-adjusted life-ye
Update use instructions for StatStrip Glucose Hospital Meter Systems due to the potential for glucose results to be assigned to the incorrect patient.
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology found.
Reason for Recall (Class II): Lack of assurance of sterility.
Reason for Recall (Class II): Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1717-1727, October 29, 2026.
To investigate the relationship between obesity, body mass index (BMI) rebound, body composition changes, associated factors (e.g., diet, physical activity), and cardiovascular risk factor status in a longitudinal study of young children, a
This study aimed therefore to evaluate bone density (BD) and OPG levels in the peri-implant crevicular fluid (PICF) in lased controlled type II Diabetes Mellitus (T2DM) patients versus non-lased T2DM patients. 40 T2DM patients were included
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
